Annexon (ANNX) Assets Average (2020 - 2026)
Annexon (ANNX) posted quarterly Assets Average of $270.2 million for Q1 2026, down 17.25% year-over-year from $326.5 million in Q1 2025, and up 6.66% quarter-over-quarter from $253.4 million in Q4 2025.
Annexon (ANNX) Assets Average (2020 - 2026) Analysis & Trends
Annexon's Assets Average history runs 7 years deep, the most recent figure standing at $270.2 million for Q1 2026.
- In Q1 2026, Assets Average fell 17.25% year-over-year to $270.2 million; the TTM figure through Mar 2026 stood at $270.2 million (down 17.25% YoY), while the FY2025 annual figure was $313.8 million, down 3.1% from the prior year.
- Assets Average for Q1 2026 stood at $270.2 million, up from $253.4 million in the prior quarter.
- The five-year high for Assets Average was $392.4 million in Q3 2024, with the low at $218.4 million in Q3 2023.
- The 5-year median for Assets Average is $270.2 million (2026), against an average of $285.9 million.
- The sharpest annual moves came in 2024 and 2025: Assets Average jumped 79.67% in 2024, then plunged 37.1% in 2025.
- Annexon's Assets Average stood at $298.9 million in 2022, then dropped by 16.11% to $250.7 million in 2023, then jumped by 45.34% to $364.4 million in 2024, then slumped by 30.48% to $253.4 million in 2025, then advanced by 6.66% to $270.2 million in 2026.
- Business Quant data shows ANNX's Assets Average at $270.2 million in Q1 2026, $253.4 million in Q4 2025, and $246.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | 254.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 254.48 Mn |
| Mar 31, 2026 | 270.23 Mn |
| Dec 31, 2025 | 253.36 Mn |
| Sep 30, 2025 | 246.86 Mn |
| Jun 30, 2025 | 283.80 Mn |
| Mar 31, 2025 | 326.55 Mn |
| Dec 31, 2024 | 364.42 Mn |
| Sep 30, 2024 | 392.43 Mn |
| Jun 30, 2024 | 355.08 Mn |
| Mar 31, 2024 | 300.87 Mn |
| Dec 31, 2023 | 250.75 Mn |
| Sep 30, 2023 | 218.41 Mn |
| Jun 30, 2023 | 250.90 Mn |
| Mar 31, 2023 | 276.94 Mn |
| Dec 31, 2022 | 298.91 Mn |
| Sep 30, 2022 | 266.71 Mn |
| Jun 30, 2022 | 235.64 Mn |
| Mar 31, 2022 | 268.80 Mn |
| Dec 31, 2021 | 298.60 Mn |
| Sep 30, 2021 | 320.97 Mn |